{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023088","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.979757+00:00","generated_at":"2026-06-05T06:47:42.377918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025","bullets":["Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.","4D-150 interim data in wet AMD: favorable safety, no significant inflammation; 24-week data reduced treatment burden vs aflibercept.","Phase 3 trial for 4D-150 in wet AMD expected to start Q1 2025; FDA RMAT and EMA PRIME designations.","Pipeline progress: 4D-710 CF positive interim data; 4D-310 Fabry cardiac improvements; IND for 4D-175 GA expected Q2 2024.","Strategic partnerships: Astellas (up to $942.5M milestones) for ophthalmic vectors; Arbor for CNS gene editing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023088","json":"https://secwatch.observer/filing/0000950170-24-023088.json","markdown":"https://secwatch.observer/filing/0000950170-24-023088.md","text":"https://secwatch.observer/filing/0000950170-24-023088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/0000950170-24-023088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/fdmt-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:47:42.377918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba9985a97cbf61c6f6062c0d53ac2999ca7e5fd5","claim":"4D Molecular Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/0000950170-24-023088-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}